Pharmacogenetic analysis of human steroid 5-α reductase type II: Comparison of finasteride and dutasteride

Journal of Molecular Endocrinology

Volumn 34, Issue 3, 2005, Pages 617-623

  Makridakis, Nick ^a   Reichardt, Juergen K V ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; IN VITRO STUDY; INHIBITION KINETICS; PHARMACOGENETICS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE;

AZASTEROIDS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; PHARMACOGENETICS; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 21344463569     PISSN: 09525041     EISSN: None     Source Type: Journal    
DOI: 10.1677/jme.1.01725     Document Type: Article

References (22)

1. Bramson HN, Hermann D, Batchelor KW, Lee FW, James MK & Frye SV 1997 Unique preclinical characteristics of GG745, a potent dual inhibitor of 5AR. Journal of Pharmacology and Experimental Therapeutics 282 1496-1502.
2. Brown CT & Nuttall MC 2003 Dutasteride: a new 5-alpha reductase inhibitor for men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. International Journal of Clinical Practice 57 705-709.
3. Cheng E, Lee C & Grayhack J 1993 Endocrinology of the prostate. In Prostate Diseases, pp 57-71. Eds H Lepor & RK Lawson. Philadelphia, PA: WB Saunders.
4. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB & Hobbs S 2004 Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5 alpha-reductase inhibitor. Journal of Clinical Endocrinology and Metabolism 89 2179-2184.
5. Faller B, Farley D & Nick H 1993 Finasteride: a slow-binding 5 alpha-reductase inhibitor. Biochemistry 32 5705-5710.
6. Frye SV, Bramson HN, Herman DJ, Lee FW, Sinhababu AK & Tian G 1998 Discovery and development of GG745, a potent inhibitor of both isozymes of 5 alpha-reductase. Pharmaceutical Biotechnology 11 393-422.
7. Jaffe JM, Malkowicz SB, Walker SH, MacBride S, Peschel R, Tomaszewski J, van Arsdalen K, Wein AJ & Rebbeck TR 2000 Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Research 60 1626-1630.
8. Kyte J & Doolittle RF 1982 A simple method for displaying the hydropathic character of a protein. Journal of Molecular Biology 157 105-132.
9. Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperto-McGinely J, Andriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner E, Waldstreicher J. The Finasteride Study Group (2003) Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology 61 791-796.
10. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM & Waldstreicher J 1998 The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. New England Journal of Medicine 338 557-563.
11. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE & Reichardt JKV 1999 A missense substitution in the SRD5A2 gene is associated with prostate cancer in African-American and Hispanic men in Los Angeles. Lancet 354 975-978.
12. Makridakis NM, di Salle E & Reichardt JKV 2000 Biochemical and pharmacogenetic dissection of steroid 5α-reductase type II. Pharmacogenetics 10 407-413.
13. Makridakis NM, Akalu A & Reichardt JKV 2004 Identification and characterization of somatic steroid 5α-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene 23 7399-7405.
14. Moss ML, Kuzmic P, Stuart JD, Tian G, Peranteau AG, Frye SV, Kadwell SH, Kost TA, Overton LK & Patel IR 1996 Inhibition of human steroid 5 alpha reductases types I and II by 6-aza-steroids: structural determinants of one-step vs two-step mechanism. Biochemistry 35 3457-3464.
15. Ross RK, Pike MC, Coetzee GA, Reichardt JKV, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN & Henderson BE 1998 Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Research 58 4497-4504.
16. Russell DW & Wilson JD 1994 Steroid 5 alpha-reductase: two genes/two enzymes. Annual Review of Biochemistry 63 25-61.
17. di Salle, E, Giudici D, Radice A, Zaccheo T, Ornati G, Nesi M, Panzeri A, Delos S & Martin PM 1998 PNU 157706, a novel dual type I and II 5 alpha-reductase inhibitor. Journal of Steroid Biochemistry and Molecular Biology 64 179-186.
18. Span PN, Voller MC, Smals AG, Sweep FG, Schalken JA, Feneley MR & Kirby RS 1999 Selectivity of finasteride as an in vivo inhibitor of 5 alpha-reductase isozyme enzymatic activity in the human prostate. Journal of Urology 161 332-337.
19. Stoner E 1996 5α-Reductase inhibitors/finasteride. Prostate 6 82-87.
20. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ & Coltman CA Jr 2003 The influence of finasteride on the development of prostate cancer. New England Journal of Medicine 349 215-224.
21. Tian G, Stuart JD, Moss ML, Domanico PL, Bramson HN, Patel IR, Kadwell SH, Overton LK, Kost TA, Mook RA Jr, Frye SV, Batchelor KW & Wiseman JS 1994 17 Beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1. Biochemistry 33 2291-2296.
22. Tian G, Mook RA Jr, Moss ML & Frye SV 1995 Mechanism of time-dependent inhibition of 5 alpha-reductases by delta 1-4-azasteroids: toward perfection of rates of time-dependent inhibition by using ligand-binding energies. Biochemistry 34 13433-13459.